Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome
Abstract
:1. Introduction
2. Measurement of Activity and Damage in pSS
3. Systemic Disease Activity Measurements
3.1. ESSDAI
3.2. ESSPRI
4. Systemic Disease Damage Measurements
5. Single Domain Assessment
5.1. Sicca Symptoms
5.2. Fatigue
5.3. Composite Instruments to Measure Subjective Symptoms in pSS
5.4. Quality of Life
5.5. Objective Measurements of Salivary Gland Function
5.6. Objective Assessment of Salivary Gland Structure
5.7. Histopathologic Assessment of Salivary Gland Features
5.8. Objective Assessment of Lachrymal Function
6. General Considerations
7. Future Direction: Use of Composite Indices for More Complete Assessment of pSS
Funding
Conflicts of Interest
References
- Fox, R.I. Sjögren’s syndrome. Lancet 2005, 366, 321–331. [Google Scholar] [CrossRef]
- Katsiougiannis, S.; Tenta, R.; Skopouli, F.N. Autoimmune epithelitis (Sjögren’s syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity. J. Autoimmun. 2019, 104, 102335. [Google Scholar] [CrossRef] [PubMed]
- Kroese, F.G.M.; Haacke, E.A.; Bombardieri, M. The role of salivary gland histopathology in primary Sjögren’s syndrome: Promises and pitfalls. Clin. Exp. Rheumatol. 2018, 36 (Suppl. 112), 222–233. [Google Scholar] [PubMed]
- Voulgarelis, M.; Dafni, U.G.; Isenberg, D.A.; Moutsopoulos, H.M. Malignant lymphoma in primary Sjögren’s syndrome: A multicenter, retrospective, clinical study by the European Concerted Action on Sjögren’s Syndrome. Arthritis Rheum. 1999, 42, 1765–1772. [Google Scholar] [CrossRef]
- Goules, A.V.; Argyropoulou, O.D.; Pezoulas, V.C.; Chatzis, L.; Critselis, E.; Gandolfo, S.; Ferro, F.; Binutti, M.; Donati, V.; Zandonella Callegher, S.; et al. Primary Sjögren’s syndrome of early and late onset: Distinct clinical phenotypes and lymphoma development. Front. Immunol. 2020, 11, 594096. [Google Scholar] [CrossRef] [PubMed]
- Del Papa, N.; Vitali, C. Management of primary Sjögren’s syndrome: Recent developments and new classification criteria. Ther. Adv. Musculoskelet. Dis. 2018, 10, 39–54. [Google Scholar] [CrossRef] [Green Version]
- Ramos-Casals, M.; Brito-Zerón, P.; Bombardieri, S.; Bootsma, H.; De Vita, S.; Dörner, T.; Fisher, B.A.; Gottenberg, J.E.; Hernandez-Molina, G.; Kocher, A.; et al. EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Ann. Rheum. Dis. 2020, 79, 3–18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mavragani, C.P.; Moutsopoulos, H.M. Sjögren’s syndrome: Old and new therapeutic targets. J. Autoimmun. 2020, 110, 102364. [Google Scholar] [CrossRef]
- Seror, R.; Theander, E.; Bootsma, H.; Bowman, S.J.; Tzioufas, A.; Gottenberg, J.E.; Ramos-Casals, M.; Dörner, T.; Ravaud, P.; Mariette, X.; et al. Outcome measures for primary Sjögren’s syndrome: A comprehensive review. J. Autoimmun. 2014, 51, 51–56. [Google Scholar] [CrossRef]
- Liang, M.H. Translating outcomes measurement in experimental therapeutics of systemic rheumatic disease to patient care. Rheum. Dis. Clin. N. Am. 2006, 32, 1–8. [Google Scholar] [CrossRef]
- Pincus, T.; Sokka, T. Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin. Exp. Rheumatol. 2005, 23 (Suppl. 39), S1–S9. [Google Scholar]
- Liang, M.H.; Socher, S.A.; Roberts, W.N.; Esdaile, J.M. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988, 31, 817–825. [Google Scholar] [CrossRef] [PubMed]
- American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: Measures of overall disease activity. Arthritis Rheum. 2004, 50, 3418–3426. [Google Scholar] [CrossRef] [PubMed]
- Gisev, N.; Bell, J.S.; Chen, T.F. Interrater agreement and interrater reliability: Key concepts, approaches, and applications. Res. Soc. Adm. Pharm. 2013, 9, 330–338. [Google Scholar] [CrossRef]
- Pincus, T.; Sokka, T. Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract. Res. Clin. Rheumatol. 2003, 17, 753–781. [Google Scholar] [CrossRef]
- Vitali, C.; Palombi, G.; Baldini, C.; Benucci, M.; Bombardieri, S.; Covelli, M.; Del Papa, N.; De Vita, S.; Epis, O.; Franceschini, F.; et al. Sjögren’s Syndrome Disease Damage Index and Disease Activity Index: Scoring systems for the assessment of disease damage and disease activity in Sjögren’s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007, 56, 2223–2231. [Google Scholar] [CrossRef]
- Bowman, S.J.; Sutcliffe, N.; Isenberg, D.A.; Goldblatt, F.; Adler, M.; Price, E.; Canavan, A.; Hamburger, J.; Richards, A.; Rauz, S.; et al. Sjögren’s Syndrome Clinical Activity Index (SCAI)—A systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. Rheumatology 2007, 46, 1845–1851. [Google Scholar] [CrossRef] [Green Version]
- Vitali, C.; Bencivelli, W.; Isenberg, D.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; D’Ascanio, A.; Bombardieri, S. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin. Exp. Rheumatol. 1992, 10, 541–547. [Google Scholar]
- Hay, E.M.; Bacon, P.A.; Gordon, C.; Isenberg, D.A.; Maddison, P.; Snaith, M.L.; Symmons, D.P.; Viner, N.; Zoma, A. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. 1993, 86, 447–458. [Google Scholar]
- Seror, R.; Ravaud, P.; Bowman, S.J.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjögren’s Task Force. EULAR Sjögren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann. Rheum. Dis. 2010, 69, 1103–1109. [Google Scholar] [CrossRef] [PubMed]
- Seror, R.; Ravaud, P.; Mariette, X.; Bootsma, H.; Theander, E.; Hansen, A.; Ramos-Casals, M.; Dörner, T.; Bombardieri, S.; Hachulla, E.; et al. EULAR Sjögren’s Task Force. EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI): Development of a consensus patient index for primary Sjögren’s syndrome. Ann. Rheum. Dis. 2011, 70, 968–972. [Google Scholar] [CrossRef] [PubMed]
- Seror, R.; Theander, E.; Brun, J.G.; Ramos-Casals, M.; Valim, V.; Dorner, T.; Bootsma, H.; Tzioufas, A.; Solans-Laqué, R.; Mandl, T.; et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann. Rheum. Dis. 2015, 74, 859–866. [Google Scholar] [CrossRef] [PubMed]
- Seror, R.; Mariette, X.; Bowman, S.; Baron, G.; Gottenberg, J.E.; Bootsma, H.; Theander, E.; Tzioufas, A.; Vitali, C.; Ravaud, P. European League Against Rheumatism Sjögren’s Task Force. Accurate detection of changes in disease activity in primary Sjögren’s syndrome by the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index. Arthritis Care Res. 2010, 62, 551–558. [Google Scholar] [CrossRef]
- Seror, R.; Bootsma, H.; Saraux, A.; Bowman, S.J.; Theander, E.; Brun, J.G.; Baron, G.; Le Guern, V.; Devauchelle-Pensec, V.; Ramos-Casals, M.; et al. EULAR Sjögren’s Task Force. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum Dis. 2016, 75, 382–389. [Google Scholar] [CrossRef]
- Gottenberg, J.E.; Cinquetti, G.; Larroche, C.; Combe, B.; Hachulla, E.; Meyer, O.; Pertuiset, E.; Kaplanski, G.; Chiche, L.; Berthelot, J.M.; et al. Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: Results in 78 patients of the AutoImmune and Rituximab registry. Ann. Rheum Dis. 2013, 72, 1026–1031. [Google Scholar] [CrossRef]
- Meiners, P.M.; Arends, S.; Brouwer, E.; Spijkervet, F.K.; Vissink, A.; Bootsma, H. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren’s syndrome treated with rituximab. Ann. Rheum. Dis. 2012, 71, 1297–1302. [Google Scholar] [CrossRef] [PubMed]
- Meiners, P.M.; Vissink, A.; Kroese, F.G.; Spijkervet, F.K.; Smitt-Kamminga, N.S.; Abdulahad, W.H.; Bulthuis-Kuiper, J.; Brouwer, E.; Arends, S.; Bootsma, H. Abatacept treatment reduces disease activity in early primary Sjögren’s syndrome (open-label proof of concept ASAP study). Ann. Rheum. Dis. 2014, 73, 1393–1396. [Google Scholar] [CrossRef]
- Machado, A.C.; Dos Santos, L.C.; Fidelix, T.; Lekwitch, I.; Soares, S.B.; Gasparini, A.F.; Augusto, J.V.; Junior, N.C.; Trevisani, V.F.M. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren’s syndrome. Clin. Rheumatol. 2020, 39, 243–248. [Google Scholar] [CrossRef]
- Devauchelle-Pensec, V.; Mariette, X.; Jousse-Joulin, S.; Berthelot, J.M.; Perdriger, A.; Puéchal, X.; Le Guern, V.; Sibilia, J.; Gottenberg, J.E.; Chiche, L.; et al. Treatment of primary Sjögren syndrome with rituximab: A randomized trial. Ann. Intern. Med. 2014, 160, 233–242. [Google Scholar] [CrossRef]
- Bowman, S.J.; Everett, C.C.; O’Dwyer, J.L.; Emery, P.; Pitzalis, C.; Ng, W.F.; Pease, C.T.; Price, E.J.; Sutcliffe, N.; Gendi, N.S.T.; et al. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome. Arthritis Rheumatol. 2017, 69, 1440–1450. [Google Scholar] [CrossRef] [Green Version]
- Baer, A.N.; Gottenberg, J.E.; St Clair, E.W.; Sumida, T.; Takeuchi, T.; Seror, R.; Foulks, G.; Nys, M.; Mukherjee, S.; Wong, R.; et al. Efficacy and safety of abatacept in active primary Sjögren’s syndrome: Results of a phase III, randomised, placebo-controlled trial. Ann. Rheum. Dis. 2020, 80, 339–348. [Google Scholar] [CrossRef]
- Felten, R.; Devauchelle-Pensec, V.; Seror, R.; Duffau, P.; Saadoun, D.; Hachulla, E.; Pierre Yves, H.; Salliot, C.; Perdriger, A.; Morel, J.; et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: A multicentre double-blind randomised placebo-controlled trial. Ann. Rheum. Dis. 2021, 80, 329–338. [Google Scholar] [CrossRef]
- De Wolff, L.; Arends, S.; van Nimwegen, J.F.; Bootsma, H. Ten years of the ESSDAI: Is it fit for purpose? Clin. Exp. Rheumatol. 2020, 38 (Suppl. 126), 283–290. [Google Scholar]
- Seror, R.; Bowman, S.J.; Brito-Zeron, P.; Theander, E.; Bootsma, H.; Tzioufas, A.; Gottenberg, J.E.; Ramos-Casals, M.; Dörner, T.; Ravaud, P.; et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): A user guide. RMD Open 2015, 1, e000022. [Google Scholar] [CrossRef] [Green Version]
- Seror, R.; Meiners, P.; Baron, G.; Bootsma, H.; Bowman, S.J.; Vitali, C.; Gottenberg, J.E.; Theander, E.; Tzioufas, A.; De Vita, S.; et al. EULAR Sjögren Task Force. Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies. Ann. Rheum. Dis. 2016, 75, 1945–1950. [Google Scholar] [CrossRef]
- Barry, R.J.; Sutcliffe, N.; Isenberg, D.A.; Price, E.; Goldblatt, F.; Adler, M.; Canavan, A.; Hamburger, J.; Richards, A.; Regan, M.; et al. The Sjögren’s Syndrome Damage Index—A damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatology 2008, 47, 1193–1198. [Google Scholar] [CrossRef] [Green Version]
- Alunno, A.; Bartoloni, E.; Valentini, V.; La Paglia, G.M.C.; Valentini, E.; Leone, M.C.; Marcucci, E.; Cafaro, G.; Bonifacio, A.F.; Luccioli, F.; et al. Discrepancy between subjective symptoms, objective measures and disease activity indexes: The lesson of primary Sjögren’s syndrome. Clin. Exp. Rheumatol. 2018, 36 (Suppl. 112), 210–214. [Google Scholar]
- Walt, J.; Rowe, M.; Stern, K.L. Evaluating the functional impact of dry eye: The Ocular Surface Disease Index (Abstract). Drug Inf. J. 1997, 31, 1436. [Google Scholar]
- Schiffman, R.M.; Christianson, M.D.; Jacobsen, G.; Hirsch, J.D.; Reis, B.L. Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 2000, 118, 615–621. [Google Scholar] [CrossRef]
- Thomson, W.M.; Chalmers, J.M.; Spencer, A.J.; Williams, S.M. The Xerostomia Inventory: A multi-item approach to measuring dry mouth. Community Dent. Health 1999, 16, 12–17. [Google Scholar]
- Field, E.A.; Rostron, J.L.; Longman, L.P.; Bowman, S.J.; Lowe, D.; Rogers, S.N. The development and initial validation of the Liverpool sicca index to assess symptoms and dysfunction in patients with primary Sjögren’s syndrome. J. Oral Pathol. Med. 2003, 32, 154–162. [Google Scholar] [CrossRef]
- Bowman, S.J.; Booth, D.A.; Platts, R.G.; Field, A.; Rostron, J.; UK Sjögren’s Interest Group. Validation of the Sicca Symptoms Inventory for clinical studies of Sjögren’s syndrome. J. Rheumatol. 2003, 30, 1259–1266. [Google Scholar]
- Yellen, S.B.; Cella, D.F.; Webster, K.; Blendowski, C.; Kaplan, E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J. Pain Symptom Manag. 1997, 13, 63–74. [Google Scholar] [CrossRef]
- Krupp, L.B.; LaRocca, N.G.; Muir-Nash, J.; Steinberg, A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch. Neurol. 1989, 46, 1121–1123. [Google Scholar] [CrossRef]
- Smets, E.M.; Garssen, B.; Bonke, B.; De Haes, J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 1995, 39, 315–325. [Google Scholar] [CrossRef] [Green Version]
- Seror, R.; Bowman, S. Outcome Measures in Primary Sjögren’s Syndrome. Arthritis Care Res. 2020, 72 (Suppl. 10), 134–149. [Google Scholar] [CrossRef] [PubMed]
- Bowman, S.J.; Booth, D.A.; Platts, R.G.; UK Sjögren’s Interest Group. Measurement of fatigue and discomfort in primary Sjogren’s syndrome using a new questionnaire tool. Rheumatology 2004, 43, 758–764. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bowman, S.J.; Hamburger, J.; Richards, A.; Barry, R.J.; Rauz, S. Patient-reported outcomes in primary Sjogren’s syndrome: Comparison of the long and short versions of the Profile of Fatigue and Discomfort–Sicca Symptoms Inventory. Rheumatology 2009, 48, 140–143. [Google Scholar] [CrossRef] [Green Version]
- Lackner, A.; Stradner, M.H.; Hermann, J.; Unger, J.; Stamm, T.; Graninger, W.B.; Dejaco, C. Assessing health-related quality of life in primary Sjögren’s syndrome-The PSS-QoL. Semin Arthritis Rheum. 2018, 48, 105–110. [Google Scholar] [CrossRef]
- Zhang, Q.; Wang, X.; Chen, H.; Shen, B. Sjogren’s syndrome is associated with negatively variable impacts on domains of health-related quality of life: Evidence from Short Form 36 questionnaire and a meta-analysis. Patient Prefer. Adherence 2017, 11, 905–911. [Google Scholar] [CrossRef] [Green Version]
- Navazesh, M.; Kumar, S.K. University of Southern California School of Dentistry. Measuring salivary flow: Challenges and opportunities. J. Am. Dent. Assoc. 2008, 139, 35S–40S. [Google Scholar] [CrossRef] [PubMed]
- Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; et al. European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 2002, 61, 554–558. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017, 69, 35–45. [Google Scholar] [CrossRef]
- Bookman, A.A.; Shen, H.; Cook, R.J.; Bailey, D.; McComb, R.J.; Rutka, J.A.; Slomovic, A.R.; Caffery, B. Whole stimulated salivary flow: Correlation with the pathology of inflammation and damage in minor salivary gland biopsy specimens from patients with primary Sjögren’s syndrome but not patients with sicca. Arthritis Rheum. 2011, 63, 2014–2020. [Google Scholar] [CrossRef] [PubMed]
- Meijer, J.M.; Meiners, P.M.; Vissink, A.; Spijkervet, F.K.; Abdulahad, W.; Kamminga, N.; Brouwer, E.; Kallenberg, C.G.; Bootsma, H. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62, 960–968. [Google Scholar] [CrossRef]
- Devauchelle-Pensec, V.; Pennec, Y.; Morvan, J.; Pers, J.O.; Daridon, C.; Jousse-Joulin, S.; Roudaut, A.; Jamin, C.; Renaudineau, Y.; Roué, I.Q.; et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007, 57, 310–317. [Google Scholar] [CrossRef]
- Jousse-Joulin, S.; Milic, V.; Jonsson, M.V.; Plagou, A.; Theander, E.; Luciano, N.; Rachele, P.; Baldini, C.; Bootsma, H.; Vissink, A.; et al. US-pSS Study Group. Is salivary gland ultrasonography a useful tool in Sjögren’s syndrome? A systematic review. Rheumatology 2016, 55, 789–800. [Google Scholar] [CrossRef] [Green Version]
- Luciano, N.; Ferro, F.; Bombardieri, S.; Baldini, C. Advances in salivary gland ultrasonography in primary Sjögren’s syndrome. Clin. Exp. Rheumatol. 2018, 36 (Suppl. 114), 159–164. [Google Scholar]
- van Ginkel, M.S.; Glaudemans, A.W.J.M.; van der Vegt, B.; Mossel, E.; Kroese, F.G.M.; Bootsma, H.; Vissink, A. Imaging in Primary Sjögren’s Syndrome. J. Clin. Med. 2020, 9, 2492. [Google Scholar] [CrossRef]
- Guellec, D.; Cornec, D.; Jousse-Joulin, S.; Marhadour, T.; Marcorelles, P.; Pers, J.O.; Saraux, A.; Devauchelle-Pensec, V. Diagnostic value of labial minor salivary gland biopsy for Sjögren’s syndrome: A systematic review. Autoimmun. Rev. 2013, 12, 416–420. [Google Scholar] [CrossRef]
- Fisher, B.A.; Jonsson, R.; Daniels, T.; Bombardieri, M.; Brown, R.M.; Morgan, P.; Bombardieri, S.; Ng, W.F.; Tzioufas, A.G.; Vitali, C.; et al. Sjögren’s histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren’s syndrome study group). Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren’s syndrome. Ann. Rheum. Dis. 2017, 76, 1161–1168. [Google Scholar] [CrossRef] [Green Version]
- Carubbi, F.; Cipriani, P.; Marrelli, A.; Benedetto, P.; Ruscitti, P.; Berardicurti, O.; Pantano, I.; Liakouli, V.; Alvaro, S.; Alunno, A.; et al. Efficacy and safety of rituximab treatment in early primary Sjögren’s syndrome: A prospective, multi-center, follow-up study. Arthritis Res. Ther. 2013, 15, R172. [Google Scholar] [CrossRef] [Green Version]
- Herbaut, A.; Liang, H.; Denoyer, A.; Baudouin, C.; Labbé, A. Tear film analysis and evaluation of optical quality: A review of the literature. J. Fr. Ophtalmol. 2019, 42, e21–e35. [Google Scholar] [CrossRef] [PubMed]
- Tashbayev, B.; Rusthen, S.; Young, A.; Herlofson, B.B.; Hove, L.H.; Singh, P.B.; Rykke, M.; Aqrawi, L.A.; Chen, X.; Utheim, Ø.A.; et al. Interdisciplinary, Comprehensive Oral and Ocular Evaluation of Patients with Primary Sjögren’s Syndrome. Sci. Rep. 2017, 7, 10761. [Google Scholar] [CrossRef]
- Van Bijsterveld, O.P. Diagnostic tests in the Sicca syndrome. Arch. Ophthalmol. 1969, 82, 10–14. [Google Scholar] [CrossRef]
- Whitcher, J.P.; Shiboski, C.H.; Shiboski, S.C.; Heidenreich, A.M.; Kitagawa, K.; Zhang, S.; Hamann, S.; Larkin, G.; McNamara, N.A.; Greenspan, J.S.; et al. Sjögren’s International Collaborative Clinical Alliance Research Groups. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjögren’s Syndrome International Registry. Am. J. Ophthalmol. 2010, 149, 405–415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chatzis, L.; Vlachoyiannopoulos, P.G.; Tzioufas, A.G.; Goules, A.V. New frontiers in precision medicine for Sjogren’s syndrome. Expert Rev. Clin. Immunol. 2021, 5, 1–15. [Google Scholar] [CrossRef]
- McCoy, S.S.; Bartels, C.M.; Saldanha, I.J.; Bunya, V.Y.; Akpek, E.K.; Makara, M.A.; Baer, A.N. National Sjögren’s Foundation Survey: Burden of Oral and Systemic Involvement on Quality of Life. J. Rheumatol. 2020. [Google Scholar] [CrossRef]
- New Clinical Endpoints in Primary Sjögren’s Syndrome: An Interventional Trial Based on Stratifying Patients (NECESSITY). Innovative Medicines Initiative. Available online: https://cordis.europa.eu/project/id/806975 (accessed on 11 May 2021).
- Arends, S.; Van Nimwegen, J.F.; Verstappen, G.M.; Vissink, A.; Ray, N.; Kroese, F.G.M.; Bootsma, H. Composite of relevant endpoints for Sjögren’s Syndrome (CRESS). Ann. Rheum. Dis. 2020, 79, 1026–1027. [Google Scholar] [CrossRef]
Construct Validity, Correlation Coefficient * | Reliability, ICC ° (CI 95%) | Responsiveness, SRM ^ (CI 95%) in Improved Patients | |
---|---|---|---|
Physician-oriented outcome measures | versus PhGA | n = 47 | n = 62 |
ESSDAI | 0.59 | 0.96 (0.89 to 0.98) | −0.72 (−0.97 to −0.57) |
SSDAI | 0.34 | 0.83 (0.56 to 0.94) | −0.82 (−1.06 to −0.62) |
SCAI | 0.32 | 0.95 (0.85 to 0.98) | −0.69 (−0.95 to −0.47) |
Patient-oriented outcome measures | versus PtGA | n = 62 | n = 95 |
ESSPRI | 0.70 | 0.94 (0.89 to 0.97) | −0.37 (−0.60 to −0.17)§ |
SSI | 0.65 | 0.86 (0.77 to 0.91) | −0.04 (−0.26 to +0.23) |
PROFAD | 0.58 | 0.92 (0.87 to 0.96) | −0.16 (−0.35 to +0.06) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Del Papa, N.; Minniti, A.; Maglione, W.; Pignataro, F.; Caporali, R.; Vitali, C. Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome. Biomolecules 2021, 11, 953. https://doi.org/10.3390/biom11070953
Del Papa N, Minniti A, Maglione W, Pignataro F, Caporali R, Vitali C. Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome. Biomolecules. 2021; 11(7):953. https://doi.org/10.3390/biom11070953
Chicago/Turabian StyleDel Papa, Nicoletta, Antonina Minniti, Wanda Maglione, Francesca Pignataro, Roberto Caporali, and Claudio Vitali. 2021. "Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren’s Syndrome" Biomolecules 11, no. 7: 953. https://doi.org/10.3390/biom11070953